Hi Clio,
Yes that is correct,
@Eqz was referring to the Euroz broker report & you are right, FY2023 was stated. Apacor appear to be a very experienced & well connected distributor in the UK, so that is a plus.
As Eqz said the report was quite conservative as Euroz themselves stated, so plenty of room for more licencing deals/collaborations. I did get to read it last night (thanks). Nice to see price target of $1.90.
We have had some lengthy speed humps in regulatory approvals brought about by COVID-19, but PIQ are ticking the boxes.
As for the Janssen collaboration, that is still active & keeping on top of the SGLT2i space, many new approvals since we started on this journey - USA, EU/UK and very importantly Asia in cardio-renal indications (Merck have licenced Invokana from Janssen for Asia, PIQ have excellent patent coverage across this region also, I think a big one pending is India).
From the questions
@The Rad raised at the AGM, it’s going to be very interesting what news will come out of the USA. The cost of the test & benefits afforded in preventing severe disease & also assisting with identifying patients who will benefit most from expensive drugs (SGLT2i) is a no-brainer. It’s getting it into the labs & the clinics.
I have noticed an increase in M&A and licencing in news in the diagnostics space recently & that is not surprising seeing the revenues that have come in from COVID-19, both to some Big Pharmas and Big Diagnostic Laboratories.
Also very pleased to hear of progress in Endometriosis diagnostic test - another clinically unmet need in >10% of the female population.
I am 100% in agreeance with
@Eqz Clio, we did have a brief chat last night. It’s been a tough few months holding recently for us all & things beyond the company’s control holding up progress, but off we go again & some very positive things to discuss.
(20min delay)